185 related articles for article (PubMed ID: 36910721)
21. Anti-Epcam Aptamer (Syl3c)-Functionalized Liposome for Targeted Delivery Of Doxorubicin: In Vitro And In Vivo Antitumor Studies in Mice Bearing C26 Colon Carcinoma.
Mashreghi M; Zamani P; Moosavian SA; Jaafari MR
Nanoscale Res Lett; 2020 May; 15(1):101. PubMed ID: 32383027
[TBL] [Abstract][Full Text] [Related]
22. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y
Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779
[TBL] [Abstract][Full Text] [Related]
23. Liposomal Doxorubicin: the Sphingomyelin/Cholesterol System Significantly Enhances the Antitumor Efficacy of Doxorubicin.
Meng X; Zhang H; Chen L; Wang M; Zhang K; Liu X; Deng Y; Song Y
AAPS PharmSciTech; 2023 Feb; 24(2):64. PubMed ID: 36759405
[TBL] [Abstract][Full Text] [Related]
24. Matrix metalloproteinase-sensitive size-shrinkable nanoparticles for deep tumor penetration and pH triggered doxorubicin release.
Ruan S; Cao X; Cun X; Hu G; Zhou Y; Zhang Y; Lu L; He Q; Gao H
Biomaterials; 2015 Aug; 60():100-10. PubMed ID: 25988725
[TBL] [Abstract][Full Text] [Related]
25. Accumulation, internalization and therapeutic efficacy of neuropilin-1-targeted liposomes.
Paoli EE; Ingham ES; Zhang H; Mahakian LM; Fite BZ; Gagnon MK; Tam S; Kheirolomoom A; Cardiff RD; Ferrara KW
J Control Release; 2014 Mar; 178():108-17. PubMed ID: 24434424
[TBL] [Abstract][Full Text] [Related]
26. Brain tumor-targeted delivery and therapy by focused ultrasound introduced doxorubicin-loaded cationic liposomes.
Lin Q; Mao KL; Tian FR; Yang JJ; Chen PP; Xu J; Fan ZL; Zhao YP; Li WF; Zheng L; Zhao YZ; Lu CT
Cancer Chemother Pharmacol; 2016 Feb; 77(2):269-80. PubMed ID: 26666650
[TBL] [Abstract][Full Text] [Related]
27. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH
Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782
[TBL] [Abstract][Full Text] [Related]
28. pH-Sensitive PEGylated Liposomal Silybin: Synthesis, In Vitro and In Vivo Anti-Tumor Evaluation.
Gheybi F; Alavizadeh SH; Rezayat SM; Hatamipour M; Akhtari J; Faridi Majidi R; Badiee A; Jaafari MR
J Pharm Sci; 2021 Dec; 110(12):3919-3928. PubMed ID: 34418455
[TBL] [Abstract][Full Text] [Related]
29. Doxorubicin liposomes as an investigative model to study the skin permeation of nanocarriers.
Boakye CH; Patel K; Singh M
Int J Pharm; 2015 Jul; 489(1-2):106-16. PubMed ID: 25910414
[TBL] [Abstract][Full Text] [Related]
30. Increasing the antitumor efficacy of doxorubicin-loaded liposomes with peptides anchored via a chelator lipid.
Herringson TP; Altin JG
J Drug Target; 2011 Sep; 19(8):681-9. PubMed ID: 21142652
[TBL] [Abstract][Full Text] [Related]
31. A novel and easy to prepare azo-based bioreductive linker and its application in hypoxia-sensitive cationic liposomal doxorubicin: Synthesis, characterization, in vitro and in vivo studies in mice bearing C26 tumor.
Mashreghi M; Faal Maleki M; Askarizadeh A; Farshchi H; Farhoudi L; Nasrollahzadeh MS; Rezazade Bazaz M; Hadizadeh F; Jaafari MR
Chem Phys Lipids; 2022 Sep; 247():105226. PubMed ID: 35850240
[TBL] [Abstract][Full Text] [Related]
32. Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas.
Allen C; McDonald C; Giannini C; Peng KW; Rosales G; Russell SJ; Galanis E
J Gene Med; 2004 Nov; 6(11):1216-27. PubMed ID: 15459967
[TBL] [Abstract][Full Text] [Related]
33. The role of size in PEGylated liposomal doxorubicin biodistribution and anti-tumour activity.
Dadpour S; Mehrabian A; Arabsalmani M; Mirhadi E; Askarizadeh A; Mashreghi M; Jaafari MR
IET Nanobiotechnol; 2022 Sep; 16(7-8):259-272. PubMed ID: 35983586
[TBL] [Abstract][Full Text] [Related]
34. A comprehensive mathematical model of drug release kinetics from nano-liposomes, derived from optimization studies of cationic PEGylated liposomal doxorubicin formulations for drug-gene delivery.
Haghiralsadat F; Amoabediny G; Helder MN; Naderinezhad S; Sheikhha MH; Forouzanfar T; Zandieh-Doulabi B
Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):169-177. PubMed ID: 28376641
[TBL] [Abstract][Full Text] [Related]
35. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
[TBL] [Abstract][Full Text] [Related]
36. Incorporation of a selective sigma-2 receptor ligand enhances uptake of liposomes by multiple cancer cells.
Zhang Y; Huang Y; Zhang P; Gao X; Gibbs RB; Li S
Int J Nanomedicine; 2012; 7():4473-85. PubMed ID: 22927761
[TBL] [Abstract][Full Text] [Related]
37. Multi-layered nanogels with MMP-sheddable PEG masks: Preparation and promotion of tumor cell uptake by controlling surface characteristics.
Choi JH; Lee JS; Park KM; Bae JW; Lee Y; Park KD
Colloids Surf B Biointerfaces; 2017 Aug; 156():71-78. PubMed ID: 28514710
[TBL] [Abstract][Full Text] [Related]
38. Preclinical study of Doxorubicine-loaded liposomal drug delivery for the treatment of head and neck cancer: Optimization by Box-Behnken statistical design.
Yang B
Acta Biochim Pol; 2020 Jun; 67(2):149-155. PubMed ID: 32506868
[TBL] [Abstract][Full Text] [Related]
39. Intelligent "Peptide-Gathering Mechanical Arm" Tames Wild "Trojan-Horse" Peptides for the Controlled Delivery of Cancer Nanotherapeutics.
Shi NQ; Li Y; Zhang Y; Shen N; Qi L; Wang SR; Qi XR
ACS Appl Mater Interfaces; 2017 Dec; 9(48):41767-41781. PubMed ID: 29161013
[TBL] [Abstract][Full Text] [Related]
40. Improving anti-tumour efficacy of PEGylated liposomal doxorubicin by dual targeting of tumour cells and tumour endothelial cells using anti-p32 CGKRK peptide.
Mashreghi M; Faal Maleki M; Karimi M; Kalalinia F; Badiee A; Jaafari MR
J Drug Target; 2021 Jul; 29(6):617-630. PubMed ID: 33393376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
